Lysine

Lysine

SCHEMBL587922

NCCCCC(N)C(=O)[O-].NCCCCC(N)C(=O)[O-].[Mg+2]

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.61
RNPEP Q9H4A4 1/20 0.43
GNAI3 P08754 1/20 0.43
GNAO1 P09471 1/20 0.43
GNAI1 P63096 1/20 0.43
DPP7 Q9UHL4 9/20 0.42
DPP8 Q6V1X1 5/20 0.42
DPP9 Q86TI2 5/20 0.42
DPP4 P27487 3/20 0.42
CPB2 Q96IY4 2/20 0.39
FAP Q12884 1/20 0.38
MMP2 P08253 1/20 0.37
ARG1 P05089 1/20 0.36
ARG2 P78540 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lysine SCHEMBL587923 1.00 GSR (0.61) GSRRNPEPGNAI3GNAO1GNAI1
Lysine SCHEMBL17352177 0.98 GSR (0.59) GSRRNPEPGNAI3GNAO1GNAI1
Lysine SCHEMBL17352176 0.98 GSR (0.59) GSRRNPEPGNAI3GNAO1GNAI1
SCHEMBL31241164 0.98 GSR (0.59) GSRRNPEPGNAI3GNAO1GNAI1
Lysine SCHEMBL25283016 0.95 GSR (0.61) GSRRNPEPGNAI3GNAO1GNAI1
Lysine SCHEMBL1281705 0.95 GSR (0.61) GSRRNPEPGNAI3GNAO1GNAI1
Lysine SCHEMBL5691753 0.95 GSR (0.61) GSRRNPEPGNAI3GNAO1GNAI1
Lysine SCHEMBL3427044 0.95 GSR (0.61) GSRRNPEPGNAI3GNAO1GNAI1
Lysine SCHEMBL7197544 0.95 GSR (0.61) GSRRNPEPGNAI3GNAO1GNAI1
Lysine SCHEMBL1034337 0.95 GSR (0.61) GSRRNPEPGNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4532464-A1 AGRICULTURALLY USEFUL MINERAL AMINO ACID COMPLEXES Statera Ag, LLC (US) 2025-04-09 EP claimed
EP-4351609-A1 ORAL COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS ASSOCIATED WITH MENOPAUSE Pizeta Pharma S.P.A. (IT) 2024-04-17 EP claimed
WO-2023230428-A1 AGRICULTURALLY USEFUL MINERAL AMINO ACID COMPLEXES STATERA AG, LLC (US) 2023-11-30 WO claimed
WO-2022259195-A1 ORAL COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS ASSOCIATED WITH MENOPAUSE. PIZETA PHARMA S.p.A. (IT) 2022-12-15 WO claimed
CN-111960900-A Water-soluble fertilizer containing traditional Chinese medicine sweet wormwood herb extract of multi-micro silicon-titanium polyglutamic acid 河南三泽农业科技有限公司 2020-11-20 CN claimed
CN-111869791-A Application of cysteamine magnesium as animal feed additive 辽宁菲迪饲料科技有限责任公司 2020-11-03 CN claimed
US-10583168-B1 Nutritional supplements including cardiovascular support components 4LIFE PATENTS, LLC (US) 2020-03-10 US claimed
CN-110668873-A Biological humic acid water-soluble fertilizer 吴娟 2020-01-10 CN claimed
US-9849157-B2 Cardiovascular therapy compositions 4LIFE PATENTS, LLC (US) 2017-12-26 US claimed
US-9339481-B2 Phosphate-binding magnesium salts and uses thereof CYPRESS PHARMACEUTICALS, INC. (US) 2016-05-17 US claimed
US-20150320795-A1 COMPOSITIONS AND METHODS COMPRISING POLYETHYLENE GLYCOL AND MAGNESIUM FOR TREATMENT OF NEURONAL INJURY WARSAW ORTHOPEDIC INC. 2015-11-12 US claimed
EP-2931292-A1 COMPOSITIONS AND METHODS COMPRISING POLYETHYLENE GLYCOL AND MAGNESIUM FOR TREATMENT OF NEURONAL INJURY Warsaw Orthopedic, Inc. (US) 2015-10-21 EP claimed
WO-2014093918-A1 COMPOSITIONS AND METHODS COMPRISING POLYETHYLENE GLYCOL AND MAGNESIUM FOR TREATMENT OF NEURONAL INJURY WARSAW ORTHOPEDIC, INC. (US) 2014-06-19 WO claimed
EP-2416786-A1 PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF Cypress Pharmaceutical, Inc. (US) 2012-02-15 EP claimed
US-20110045063-A2 PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF CYPRESS PHARMACEUTICAL, INC. (US) 2011-02-24 US claimed
US-7815943-B2 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition 4LIFE RESEARCH, LC (US) 2010-10-19 US claimed
WO-2010117370-A1 PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF CYPRESS PHARMACEUTICALS, INC. (US) 2010-10-14 WO claimed
US-20090269399-A1 PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF CYPRESS PHARMACEUTICAL, INC. (US) 2009-10-29 US claimed
US-20070243232-A1 Method to treat and prevent asthma attacks using throat lozenges and orally-retained liquids containing magnesium EBY III GEORGE A 2007-10-18 US claimed
US-12564644-B2 Cyclodextrin complexes of specialized proresolving mediators THETIS PHARMACEUTICALS LLC (US) 2026-03-03 US disclosed
US-20250288630-A1 HERBAL FORMULATIONS OF CARNIVOROUS PLANTS AND METHODS FOR TREATING INFLAMMATION GOWEY RESEARCH GROUP, PLLC 2025-09-18 US disclosed
EP-4132299-B1 VITALITY DIETARY SUPPLEMENT NESTLE SA (CH) 2025-06-11 EP disclosed
US-12318420-B2 Herbal formulations of carnivorous plants and methods for treating inflammation GOWEY RESEARCH GROUP, PLLC (US) 2025-06-03 US disclosed
US-20250134137-A1 MAGNESIUM SUPPLEMENT FOR POULTRY TIMAB MAGNESIUM (FR) 2025-05-01 US disclosed
EP-4532464-A1 AGRICULTURALLY USEFUL MINERAL AMINO ACID COMPLEXES Statera Ag, LLC (US) 2025-04-09 EP disclosed
EP-4486393-A2 CYCLODEXTRIN COMPLEXES OF SPECIALIZED PRORESOLVING MEDIATORS Thetis Pharmaceuticals LLC (US) 2025-01-08 EP disclosed
CN-119136842-A Cyclodextrin complexes that specialize in resolution mediators 西蒂斯制药有限责任公司 2024-12-13 CN disclosed
US-20240408229-A1 CYCLODEXTRIN COMPLEXES OF SPECIALIZED PRORESOLVING MEDIATORS THETIS PHARMACEUTICALS LLC (US) 2024-12-12 US disclosed
US-20240374538-A1 COMPOSITIONS COMPRISING NATURAL PRODUCTS FOR IMPROVING CARBOHYDRATE AND LIPID METABOLISM GROUPE NATURE PHARMA (CA) 2024-11-14 US disclosed
EP-3927350-B1 MAGNESIUM SUPPLEMENT FOR POULTRY TIMAB MAGNESIUM (FR) 2024-05-22 EP disclosed
EP-4351609-A1 ORAL COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS ASSOCIATED WITH MENOPAUSE Pizeta Pharma S.P.A. (IT) 2024-04-17 EP disclosed
US-11925688-B2 Compositions and methods relating to salts of specialized pro-resolving mediators THETIS PHARMACEUTICALS LLC (US) 2024-03-12 US disclosed
US-20240041968-A1 FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USE GOLO, LLC 2024-02-08 US disclosed
US-20240041969-A1 FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USE GOLO, LLC 2024-02-08 US disclosed
US-11883456-B2 Formulations for weight loss and methods of use GOLO, LLC (US) 2024-01-30 US disclosed
WO-2023230428-A1 AGRICULTURALLY USEFUL MINERAL AMINO ACID COMPLEXES STATERA AG, LLC (US) 2023-11-30 WO disclosed
WO-2023168245-A2 CYCLODEXTRIN COMPLEXES OF SPECIALIZED PRORESOLVING MEDIATORS THETIS PHARMACEUTICALS LLC (US) 2023-09-07 WO disclosed
US-20230241153-A1 METHODS AND COMPOSITIONS FOR UPREGULATING RNA INTERFERENCE AND ENHANCING GENE SILENCING GOWEY RESEARCH GROUP, PLLC 2023-08-03 US disclosed
EP-4189402-A2 METHOD AND COMPOSITION OF UPREGULATING RNA INTERFERENCE PROCESS Gowey Research Group PLLC (US) 2023-06-07 EP disclosed
US-20230157344-A1 VITALITY DIETARY SUPPLEMENT NESTLE SA (CH) 2023-05-25 US disclosed
CN-115925473-A Fish protein polypeptide water-soluble fertilizer and preparation method thereof 仲恺农业工程学院 2023-04-07 CN disclosed
US-20230054630-A1 SLEEP DIETARY SUPPLEMENT NESTLE SA (CH) 2023-02-23 US disclosed
EP-4132299-A1 VITALITY DIETARY SUPPLEMENT Société des Produits Nestlé S.A. (CH) 2023-02-15 EP disclosed
WO-2022259195-A1 ORAL COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS ASSOCIATED WITH MENOPAUSE. PIZETA PHARMA S.p.A. (IT) 2022-12-15 WO disclosed
US-20220347252-A1 FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USE GOLO, LLC 2022-11-03 US disclosed
US-11458182-B2 Formulations for weight loss and methods of use GOLO LLC (US) 2022-10-04 US disclosed
US-11439614-B2 Fish egg extracts, omega-3 lipid-based compositions and uses thereof BIOFLASH INC. 2022-09-13 US disclosed
CN-109562186-B Compositions and methods relating to salts of specialized proresolving mediators 西蒂斯制药有限责任公司 2022-09-13 CN disclosed
US-20220174988-A1 AMINO ACID CHELATES FOR REDUCING OXIDATIVE STRESS CRAIN SCOTT L (US) 2022-06-09 US disclosed
US-11344505-B1 Herbal formulations of carnivorous plants and methods for treating inflammation GOWEY RESEARCH GROUP, PLLC (US) 2022-05-31 US disclosed
US-20220117267-A1 MAGNESIUM SUPPLEMENT FOR POULTRY TIMAB MAGNESIUM (FR) 2022-04-21 US disclosed
US-20220031851-A1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS THETIS PHARMACEUTICALS LLC (US) 2022-02-03 US disclosed
EP-3927350-A1 MAGNESIUM SUPPLEMENT FOR POULTRY Timab Magnesium (FR) 2021-12-29 EP disclosed
US-11191840-B2 Compositions and methods relating to salts of specialized pro-resolving mediators THETIS PHARMACEUTICALS LLC (US) 2021-12-07 US disclosed
US-11141448-B2 Formulations for weight loss and methods of use GOLO LLC (US) 2021-10-12 US disclosed
US-11135298-B2 Compositions and methods relating to salts of specialized pro-resolving mediators THETIS PHARMACEUTICALS LLC (US) 2021-10-05 US disclosed
US-20210145915-A1 FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USE GOLO LLC 2021-05-20 US disclosed
US-20210138072-A1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS THETIS PHARMACEUTICALS LLC 2021-05-13 US disclosed
EP-3795179-A1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION Thetis Pharmaceuticals LLC (US) 2021-03-24 EP disclosed
US-20210060058-A1 COMPOSITIONS AND METHODS FOR TREATING HYDROGEN SULFIDE-MEDIATED HYPERDYNAMIC CIRCULATION UNM RAINFOREST INNOVATIONS 2021-03-04 US disclosed
US-20200384051-A1 HERBAL FORMULATIONS OF CARNIVOROUS PLANTS AND METHODS FOR TREATING INFLAMMATION GOWEY RESEARCH GROUP, PLLC 2020-12-10 US disclosed
CN-111960900-A Water-soluble fertilizer containing traditional Chinese medicine sweet wormwood herb extract of multi-micro silicon-titanium polyglutamic acid 河南三泽农业科技有限公司 2020-11-20 CN disclosed
CN-111902394-A Compositions and methods relating to salts of specific pro-inflammatory resolution mediators 西蒂斯制药有限责任公司 2020-11-06 CN disclosed
CN-111869791-A Application of cysteamine magnesium as animal feed additive 辽宁菲迪饲料科技有限责任公司 2020-11-03 CN disclosed
WO-2020219756-A1 AMINO ACID CHELATES FOR REDUCING OXIDATIVE STRESS CRAIN, SCOTT, L. (US) 2020-10-29 WO disclosed
EP-3717451-A1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS Thetis Pharmaceuticals LLC (US) 2020-10-07 EP disclosed
US-10765718-B2 Formulations for weight loss and methods of use GOLO LLC (US) 2020-09-08 US disclosed
US-20200261530-A1 FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USE GOLO LLC 2020-08-20 US disclosed
EP-3454907-B1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION THETIS PHARMACEUTICALS LLC (US) 2020-07-22 EP disclosed
US-20200179521-A1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS THETIS PHARMACEUTICALS LLC (US) 2020-06-11 US disclosed
US-20200170280-A1 METAL COMPLEX OR METAL CHELATE COMPOSITIONS COMPRISING MINIMAL NANOPARTICLES JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT 2020-06-04 US disclosed
US-10638785-B2 Liquid dietary supplement formulation compositions Watermins, LLC (US) 2020-05-05 US disclosed
US-10583168-B1 Nutritional supplements including cardiovascular support components 4LIFE PATENTS, LLC (US) 2020-03-10 US disclosed
CN-110668873-A Biological humic acid water-soluble fertilizer 吴娟 2020-01-10 CN disclosed
US-10420843-B2 Compositions and methods relating to salts of specialized pro-resolving mediators THETIS PHARMACEUTICALS LLC (US) 2019-09-24 US disclosed
US-20190223487-A1 LIQUID DIETARY SUPPLEMENT FORMULATION COMPOSITIONS Watermins, LLC 2019-07-25 US disclosed
EP-3218466-B1 PROCESS FOR PRODUCING A BREWED BEVERAGE OR FOR ISOMERISING ALPHA ACIDS IFAST NV (BE) 2019-04-24 EP disclosed
US-10251412-B2 Liquid dietary supplement formulation compositions WATERMINS LLC 2019-04-09 US disclosed
EP-3454907-A1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION Thetis Pharmaceuticals LLC (US) 2019-03-20 EP disclosed
US-10150784-B2 Crystal polymorph of magnesium glycinate dihydrate and process for its preparation CYPRESS PHARMACEUTICALS, INC. (US) 2018-12-11 US disclosed
US-10130719-B2 Compositions and methods relating to salts of specialized pro-resolving mediators THETIS PHARMACEUTICALS LLC (US) 2018-11-20 US disclosed
EP-2791066-B1 LIQUID DIETARY SUPPLEMENT FORMULATION COMPOSITIONS WATERMINS LLC (US) 2018-10-31 EP disclosed
EP-3157936-B1 MINERAL AMINO-ACID COMPLEXES OF ACTIVE AGENTS THETIS PHARMACEUTICALS LLC (US) 2018-10-17 EP disclosed
WO-2018176150-A1 FISH EGG EXTRACTS, OMEGA-3 LIPID-BASED COMPOSITIONS AND USES THEREOF BIOFLASH INC. (CA) 2018-10-04 WO disclosed
US-20180280333-A1 FISH EGG EXTRACTS, OMEGA-3 LIPID-BASED COMPOSITIONS AND USES THEREOF BIOFLASH INC. (CA) 2018-10-04 US disclosed
WO-2018144911-A1 FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USE GOLO LLC (US) 2018-08-09 WO disclosed
US-20180214502-A1 FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USE GOLO LLC 2018-08-02 US disclosed
US-20180200375-A1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS THETIS PHARMACEUTICALS LLC (US) 2018-07-19 US disclosed
US-9999626-B2 Mineral amino-acid complexes of active agents THETIS PHARMACEUTICALS LLC (US) 2018-06-19 US disclosed
US-20180161365-A1 Phosphate-Binding Magnesium Salts And Uses Thereof CURRAX PHARMACEUTICALS LLC 2018-06-14 US disclosed
EP-2931292-B1 COMPOSITIONS AND METHODS COMPRISING POLYETHYLENE GLYCOL AND MAGNESIUM FOR TREATMENT OF NEURONAL INJURY WARSAW ORTHOPEDIC INC (US) 2018-06-13 EP disclosed
US-20180110751-A1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS THETIS PHARMACEUTICALS LLC 2018-04-26 US disclosed
US-9889157-B2 Phosphate-binding magnesium salts and uses thereof CYPRESS PHARMACEUTICALS, INC. (US) 2018-02-13 US disclosed
US-9849157-B2 Cardiovascular therapy compositions 4LIFE PATENTS, LLC (US) 2017-12-26 US disclosed
WO-2017210604-A1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION THETIS PHARMACEUTICALS LLC (US) 2017-12-07 WO disclosed
EP-3218466-A1 PROCESS FOR PRODUCING A BREWED BEVERAGE OR FOR BREWING A BEER Ifast NV (BE) 2017-09-20 EP disclosed
US-20170202875-A1 Phosphate-Binding Magnesium Salts And Uses Thereof WILMINGTON SAVINGS FUND SOCIETY, FSB 2017-07-20 US disclosed
EP-3157936-A1 MINERAL AMINO-ACID COMPLEXES OF ACTIVE AGENTS Thetis Pharmaceuticals LLC (US) 2017-04-26 EP disclosed
EP-3157936-A1 MINERAL AMINO-ACID COMPLEXES OF ACTIVE AGENTS Thetis Pharmaceuticals LLC (US) 2017-04-26 EP disclosed
US-9610267-B2 Phosphate-binding magnesium salts and uses thereof CYPRESS PHARMACEUTICALS, INC. (US) 2017-04-04 US disclosed
US-20160326188-A1 Crystal Polymorph Of Magnesium Glycinate Dihydrate And Process For Its Preparation WILMINGTON SAVINGS FUND SOCIETY, FSB 2016-11-10 US disclosed
US-20160256420-A1 Phosphate-Binding Magnesium Salts And Uses Thereof WILMINGTON SAVINGS FUND SOCIETY, FSB 2016-09-08 US disclosed
US-9394318-B2 Crystal polymorph of magnesium glycinate dihydrate and process for its preparation CYPRESS PHARMACEUTICALS, INC. (US) 2016-07-19 US disclosed
US-20160199385-A1 Mineral Amino-Acid Complexes of Active Agents CONNECTICUT INNOVATIONS, INC., AS COLLATERAL AGENT 2016-07-14 US disclosed
US-20160192689-A1 ENCAPSULATED FUNCTIONAL FOOD COMPOSITIONS Incredible Foods, Inc. 2016-07-07 US disclosed
EP-3027058-A1 ENCAPSULATED FUNCTIONAL FOOD COMPOSITIONS Wikifoods, Inc. (US) 2016-06-08 EP disclosed
WO-2016075308-A1 PROCESS FOR PRODUCING A BREWED BEVERAGE OR FOR BREWING A BEER IFAST NV (BE) 2016-05-19 WO disclosed
US-9339481-B2 Phosphate-binding magnesium salts and uses thereof CYPRESS PHARMACEUTICALS, INC. (US) 2016-05-17 US disclosed
US-9242008-B2 Mineral amino-acid complexes of fatty acids THETIS PHARMACEUTICALS LLC (US) 2016-01-26 US disclosed
US-20150366980-A1 Mineral Amino-Acid Complexes of Fatty Acids CONNECTICUT INNOVATIONS, INC., AS COLLATERAL AGENT 2015-12-24 US disclosed
WO-2015195491-A1 MINERAL AMINO-ACID COMPLEXES OF ACTIVE AGENTS THETIS PHARMACEUTICALS LLC (US) 2015-12-23 WO disclosed
WO-2015195491-A1 MINERAL AMINO-ACID COMPLEXES OF ACTIVE AGENTS THETIS PHARMACEUTICALS LLC (US) 2015-12-23 WO disclosed
US-20150320795-A1 COMPOSITIONS AND METHODS COMPRISING POLYETHYLENE GLYCOL AND MAGNESIUM FOR TREATMENT OF NEURONAL INJURY WARSAW ORTHOPEDIC INC. 2015-11-12 US disclosed
EP-2931292-A1 COMPOSITIONS AND METHODS COMPRISING POLYETHYLENE GLYCOL AND MAGNESIUM FOR TREATMENT OF NEURONAL INJURY Warsaw Orthopedic, Inc. (US) 2015-10-21 EP disclosed
WO-2015017625-A1 ENCAPSULATED FUNCTIONAL FOOD COMPOSITIONS WIKIFOODS, INC. (US) 2015-02-05 WO disclosed
EP-2791066-A1 LIQUID DIETARY SUPPLEMENT FORMULATION COMPOSITIONS Wadhwa, Manpreet, S. (US) 2014-10-22 EP disclosed
US-20140186408-A1 CRYSTAL POLYMORPH OF MAGNESIUM GLYCINATE DIHYDRATE AND PROCESS FOR ITS PREPARATION CYPRESS PHARMACEUTICAL, INC. (US) 2014-07-03 US disclosed
WO-2014093918-A1 COMPOSITIONS AND METHODS COMPRISING POLYETHYLENE GLYCOL AND MAGNESIUM FOR TREATMENT OF NEURONAL INJURY WARSAW ORTHOPEDIC, INC. (US) 2014-06-19 WO disclosed
US-20140161955-A1 Liquid Dietary Supplement Formulation Compositions WATERMINS LLC 2014-06-12 US disclosed
WO-2013090402-A1 LIQUID DIETARY SUPPLEMENT FORMULATION COMPOSITIONS WADHWA MANPREET S (US) 2013-06-20 WO disclosed
US-20120282352-A1 PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF CYPRESS PHARMACEUTICAL, INC. (US) 2012-11-08 US disclosed
US-8247000-B2 Phosphate-binding magnesium salts and uses thereof CYPRESS PHARMACEUTICAL, INC. (US) 2012-08-21 US disclosed
US-8236358-B1 Phosphate-binding magnesium salts and uses thereof CYPRESS PHARMACEUTICAL, INC. (US) 2012-08-07 US disclosed
US-20120195964-A1 PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF CYPRESS PHARMACEUTICAL, INC. (US) 2012-08-02 US disclosed
EP-2416786-A1 PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF Cypress Pharmaceutical, Inc. (US) 2012-02-15 EP disclosed
US-20110045063-A2 PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF CYPRESS PHARMACEUTICAL, INC. (US) 2011-02-24 US disclosed
US-20110033414-A1 CARDIOVASCULAR THERAPY COMPOSITION INCLUDING TRANSFER FACTOR AND THERAPEUTIC METHODS INCLUDING USE OF THE COMPOSITION 4LIFE RESEARCH, LC (US) 2011-02-10 US disclosed
US-7815943-B2 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition 4LIFE RESEARCH, LC (US) 2010-10-19 US disclosed
WO-2010117370-A1 PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF CYPRESS PHARMACEUTICALS, INC. (US) 2010-10-14 WO disclosed
US-7811352-B2 Fertilizer compositions and methods of using ARCHER-DANIELS-MIDLAND COMPANY (US) 2010-10-12 US disclosed
US-7776124-B2 Fertilizer compositions and methods of using ARCHER-DANIELS-MIDLAND COMPANY (US) 2010-08-17 US disclosed
US-20090269399-A1 PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF CYPRESS PHARMACEUTICAL, INC. (US) 2009-10-29 US disclosed
EP-1937610-A2 FERTILIZER COMPOSITIONS AND METHODS OF USING Archer-Daniels-Midland Company (US) 2008-07-02 EP disclosed
US-20080134737-A1 FERTILIZER COMPOSITIONS AND METHODS OF USING ARCHER-DANIELS-MIDLAND COMPANY (US) 2008-06-12 US disclosed
US-20070292493-A1 Pharmaceutical composition and method for the transdermal delivery of calcium BRIERRE BARBARA T 2007-12-20 US disclosed
US-20070243232-A1 Method to treat and prevent asthma attacks using throat lozenges and orally-retained liquids containing magnesium EBY III GEORGE A 2007-10-18 US disclosed
US-20070131010-A1 FERTILIZER COMPOSITIONS AND METHODS OF USING ARCHER-DENIELS-MIDLAND COMPANY (US) 2007-06-14 US disclosed
WO-2007047350-A2 FERTILIZER COMPOSITIONS AND METHODS OF USING ARCHER-DANIELS-MIDLAND COMPANY (US) 2007-04-26 WO disclosed
WO-2005091872-A2 PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TRANSDERMAL DELIVERY OF MAGNESIUM BRIERRE BARBARA T (US) 2005-10-06 WO disclosed
US-20050196434-A1 Pharmaceutical composition and method for the transdermal delivery of magnesium BRIERRE BARBARA T (US) 2005-09-08 US disclosed
US-20050196433-A1 Pharmaceutical composition and method for the transdermal delivery of magnesium BRIERRE BARBARA T (US) 2005-09-08 US disclosed
US-20040126432-A1 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition 4LIFE PATENTS, LLC 2004-07-01 US disclosed
WO-2004017916-A2 CARDIOVASCULAR THERAPY COMPOSITION INCLUDING TRANSFER FACTOR AND THERAPEUTIC METHODS INCLUDING USE OF THE COMPOSITION 4LIFE RESEARCH, LC (US) 2004-03-04 WO disclosed
US-6451341-B1 ADMINISTERING TO ANIMAL DIETARY SUPPLEMENT COMPRISING BUTYLATED HYDROXYTOLUENE(BHT), BUTYLATED HYDROXYANISOLE(BHA), VITAMIN E, AND B-CAROTENE TO PREVENT SKIN CANCER BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-09-17 US disclosed
EP-0514451-B1 DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS LIFESCIENCE CORP (US) 1997-01-15 EP disclosed
EP-0514451-A1 DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS. UNIV TEXAS (US) 1992-11-25 EP disclosed
WO-1991011117-A2 DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1991-08-08 WO disclosed
WO-1991011117-A2 DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1991-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10420843-B2 Compositions and methods relating to salts of specialized pro-resolving mediators PTGER1, PTGER4, PTGER2 GSR 1679/4885RNPEP 1435/4885GNAI3 1546/4885
US-20220031851-A1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS ALOX15B, LTB4R2, ALOX5 GSR 705/4885RNPEP 1157/4885GNAI3 663/4885
US-20180200375-A1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS ALOX15B, LTB4R2, ALOX5 GSR 705/4885RNPEP 1157/4885GNAI3 663/4885
US-11191840-B2 Compositions and methods relating to salts of specialized pro-resolving mediators ALOX5, ALOX15B, ALOX15 GSR 802/4885RNPEP 1123/4885GNAI3 746/4885
US-10150784-B2 Crystal polymorph of magnesium glycinate dihydrate and process for its preparation G6PC1, MGAM, SLC5A1 GSR 1733/4885RNPEP 2841/4885GNAI3 283/4885
US-20160326188-A1 Crystal Polymorph Of Magnesium Glycinate Dihydrate And Process For Its Preparation G6PC1, MGAM, SLC5A1 GSR 1733/4885RNPEP 2841/4885GNAI3 283/4885
US-20150366980-A1 Mineral Amino-Acid Complexes of Fatty Acids FABP4, FABP3, SLC27A2 GSR 2273/4885RNPEP 1281/4885GNAI3 2204/4885
US-20140186408-A1 CRYSTAL POLYMORPH OF MAGNESIUM GLYCINATE DIHYDRATE AND PROCESS FOR ITS PREPARATION G6PC1, MGAM, SLC5A1 GSR 1733/4885RNPEP 2841/4885GNAI3 283/4885
US-11925688-B2 Compositions and methods relating to salts of specialized pro-resolving mediators ALOX15B, LTB4R2, ALOX5 GSR 705/4885RNPEP 1157/4885GNAI3 663/4885
US-20200179521-A1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS ALOX15B, LTB4R2, ALOX5 GSR 705/4885RNPEP 1157/4885GNAI3 663/4885
US-11135298-B2 Compositions and methods relating to salts of specialized pro-resolving mediators PTGER1, PTGIS, PTGER4 GSR 2032/4885RNPEP 1288/4885GNAI3 1115/4885
US-20210138072-A1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS ALOX5, ALOX15B, ALOX15 GSR 802/4885RNPEP 1123/4885GNAI3 746/4885
US-20180110751-A1 COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS ALOX15B, LTB4R2, ALOX5 GSR 705/4885RNPEP 1157/4885GNAI3 663/4885
US-20160199385-A1 Mineral Amino-Acid Complexes of Active Agents S100A6, S100A4, SLC7A1 GSR 4169/4885RNPEP 740/4885GNAI3 1971/4885
US-20240408229-A1 CYCLODEXTRIN COMPLEXES OF SPECIALIZED PRORESOLVING MEDIATORS PTGER1, LTB4R2, ALOX5 GSR 1794/4885RNPEP 2760/4885GNAI3 1591/4885
US-10130719-B2 Compositions and methods relating to salts of specialized pro-resolving mediators ALOX5, ALOX15, ALOX12 GSR 1223/4885RNPEP 976/4885GNAI3 1150/4885
US-12564644-B2 Cyclodextrin complexes of specialized proresolving mediators ALOX15, ALOX12, PTGES GSR 2736/4885RNPEP 3892/4885GNAI3 2830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.